SCHEMBL338789

SCHEMBL338789

O=[N+]([O-])c1ccccc1Nc1ccc(Br)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 5/20 0.74
TDP1 Q9NUW8 3/20 0.74
L3MBTL1 Q9Y468 3/20 0.74
ALDH1A1 P00352 3/20 0.74
CASP7 P55210 1/20 0.74
MAPT P10636 6/20 0.71
MEN1 O00255 5/20 0.71
KMT2A Q03164 5/20 0.71
GAA P10253 2/20 0.71
PKM P14618 1/20 0.71
IDO1 P14902 1/20 0.55
EPAS1 Q99814 1/20 0.52
RAB9A P51151 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
NPC1 O15118 1/20 0.48
GBA1 P04062 1/20 0.48
HCAR3 P49019 1/20 0.48
WNK1 Q9H4A3 1/20 0.47
POLB P06746 2/20 0.47
MAPK13 O15264 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11506844 0.91 ALDH1A1 (0.89) MAPK1TDP1L3MBTL1ALDH1A1CASP7
SCHEMBL11507400 0.86 ALDH1A1 (0.79) MAPK1TDP1L3MBTL1ALDH1A1CASP7
SCHEMBL230292 0.85 TDP1 (1.00) MAPK1TDP1L3MBTL1ALDH1A1CASP7
SCHEMBL31333098 0.85 TDP1 (1.00) MAPK1TDP1L3MBTL1ALDH1A1CASP7
SCHEMBL27760804 0.85 MAPK1 (0.54) MAPK1TDP1L3MBTL1ALDH1A1CASP7
SCHEMBL5718635 0.84 MAPK1 (0.77) MAPK1TDP1L3MBTL1ALDH1A1CASP7
Nitrogen SCHEMBL27702068 0.83 MAPK1 (0.51) MAPK1TDP1L3MBTL1ALDH1A1CASP7
SCHEMBL11676980 0.83 MAPK1 (0.74) MAPK1TDP1L3MBTL1ALDH1A1CASP7
SCHEMBL497223 0.83 MAPK1 (0.74) MAPK1TDP1L3MBTL1ALDH1A1CASP7
SCHEMBL109703 0.83 MAPT (1.00) MAPK1TDP1L3MBTL1ALDH1A1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106831864-B Based on phenylbenzimidazol monopole thermal excitation delayed fluorescence main body, the preparation method and application of electron transport material 黑龙江大学 2019-04-19 CN claimed
CN-106831864-A Based on phenylbenzimidazol monopole thermal excitation delayed fluorescence main body, the preparation method and application of electron transport material 黑龙江大学 2017-06-13 CN claimed
EP-1602648-B2 Nitrogen-containing heterocycle derivative and organic electroluminescent element using the same IDEMITSU KOSAN CO (JP) 2025-03-26 EP disclosed
US-11056651-B2 Organic light-emitting device SAMSUNG DISPLAY CO., LTD. (KR) 2021-07-06 US disclosed
CN-106450039-B Organic light emitting device 三星显示有限公司 2020-03-06 CN disclosed
US-RE47654-E1 Organic electroluminescence device IDEMITSU KOASN CO., LTD. (JP) 2019-10-22 US disclosed
CN-106831864-B Based on phenylbenzimidazol monopole thermal excitation delayed fluorescence main body, the preparation method and application of electron transport material 黑龙江大学 2019-04-19 CN disclosed
US-9974779-B2 Piperidine derivatives as human papilloma virus inhibitors VAXART, INC. (US) 2018-05-22 US disclosed
US-20180021318-A9 PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS VAXART, INC. 2018-01-25 US disclosed
US-9748496-B2 Nitrogenated heterocyclic derivative, electron-transporting material for organic electroluminescent elements, and organic electroluminescent element using same IDEMITSU KOSAN CO., LTD. (JP) 2017-08-29 US disclosed
EP-2524913-B1 NITROGENATED HETEROCYCLIC RING DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME IDEMITSU KOSAN CO (JP) 2017-07-26 EP disclosed
WO-2007135106-A1 PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS ANACONDA PHARMA (FR) 2007-11-29 WO disclosed
US-20070200490-A1 Nitrogenous Heterocycle Derivative, And Organic Electroluminescent Element Employing The Same IDEMITSU KASON CO.LTD (JP) 2007-08-30 US disclosed
US-20070138950-A1 NITROGENOUS HETEROCYCLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2007-06-21 US disclosed
US-20070138950-A1 NITROGENOUS HETEROCYCLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2007-06-21 US disclosed
EP-1734038-A1 NITROGENOUS HETEROCYCLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2006-12-20 EP disclosed
US-20060147747-A1 2-[4-(10-naphthalene-2-yl-anthracene-9-yl)-phenyl]-1-phenyl-1H-benzimidazole; elevation of luminance and of efficiency in light emission even under low driving voltage IDEMITSU KOSAN CO., LTD. (JP) 2006-07-06 US disclosed
CN-1784388-A Nitrogen-containing heterocyclic derivative and organic electroluminescent element using same IDEMITSU KOSAN CO (JP) 2006-06-07 CN disclosed
EP-1602648-A1 NITROGEN-CONTAINING HETEROCYCLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2005-12-07 EP disclosed
EP-0374991-A1 New antimicrobial phenazine derivatives, method for their preparation, compositions containing them, and their use in therapy WESTMART HILL LIMITED (IE) 1990-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070200490-A1 Nitrogenous Heterocycle Derivative, And Organic Electroluminescent Element Employing The Same RPS3A, NCOA3, HNRNPA0 MAPK1 1144/4885TDP1 2403/4885L3MBTL1 816/4885
US-20180021318-A9 PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS POLI, VHL, EBNA1BP2 MAPK1 3238/4885TDP1 1151/4885L3MBTL1 4048/4885
US-20070138950-A1 NITROGENOUS HETEROCYCLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME EHD1, HCN2, ODC1 MAPK1 1605/4885TDP1 1246/4885L3MBTL1 1547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.